Posts By: Karen Jones

New Study Asks: When Does MS Begin?

Source National Multiple Sclerosis Society: Researchers from the Harvard T.H. Chan School of Public Health in Boston and collaborators report on a study that examined blood (serum) samples from 60 military personnel who went on to develop multiple sclerosis years later. Compared to samples from a control group, those who eventually developed MS showed higher than… Read more »

MS Progression Affected by Degree of Relapse Recovery and Timing of DMT Use, Study Says

Source Multiple Sclerosis News Today:  Recovering well after a first relapse and starting a disease-modifying therapy (DMT) immediately afterwards considerably increases the likelihood of slowing progression in multiple sclerosis (MS), a study suggests. Its findings support relapse recovery as a critical factor for DMT initiation, and one that should be assessed routinely in MS clinical trials, researchers said. The… Read more »

Brain Regeneration Impaired in Progressive MS, Unaffected By DMTs, Study Reports

Source Multiple Sclerosis News Today: Regeneration in the brain is reduced in people with primary progressive multiple sclerosis (PPMS), but enhanced during disease activity in those with relapsing-remitting MS (RRMS), a study reports. The results also show that regeneration is unaffected by treatment with disease-modifying therapies (DMTs), as shown by the levels of a regeneration marker in the brain called growth-associated protein… Read more »

Autologous Hematopoietic Stem Cell Transplantation versus Best Available Therapy for Multiple Sclerosis

Source Pipeline Review: Clinical Trial of Autologous Hematopoietic Stem Cell Transplantation versus Best Available Therapy for Multiple Sclerosis (BEAT-MS) Begins Enrollment. The Immune Tolerance Network (ITN) opened the BEAT-MS clinical trial for enrollment. BEAT-MS or “Best Available Therapy vs. Autologous Hematopoietic Stem Cell Transplant (AHSCT) for MS” will investigate high dose immunosuppression followed by AHSCT –… Read more »

Plegridy approved for relapsing remitting MS in England

Source MS Trust: NICE has published its final decision recommending that Plegridy can be prescribed by the NHS for relapsing-remitting MS. In May 2018, NICE carried out a review of several of the MS drugs and decided that Avonex, Extavia, Rebif, Copaxone and Brabio should continue to be available on the NHS in England. At the time, NICE was unable to make a recommendation on… Read more »

Search About us Blog Membership Contact Newsletters Home How we can help Your first visit About MS Support us Events Donate The MS Society went to 10 Downing Street with their ambassador Janis Winehouse

Source MS Society: The MS Society went to 10 Downing Street yesterday with their ambassador Janis Winehouse and campaigner Ashley Arundale to deliver a message to the PM: Unfair PIP assessments must change. “More than 21,000 of us have signed an open letter demanding the UK Government makes changes to Personal Independence Payment (PIP). The open… Read more »

It’s time to look at mountain escapes with a fresh perspective.

Source Winter Sports Travel:  Making Travel Accessible.  Winter sports are becoming more accessible than ever before.  But finding the right place or activity when you’re living with a challenging condition can be tough.  Try this tool to find sports and resorts in Europe that are tailored to your needs.  Click here. 

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART)

Source The Lancet: Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. We aimed to test the efficacy of these drugs in an efficient manner with respect to time, cost, and patient resource. Methods We… Read more »

Siponimod licensed for secondary progressive MS

Source MS Society: This week the European Medicines Agency (EMA) granted a license for siponimod (brand name Mayzent) to treat adults with secondary progressive MS with active disease. That makes siponimod the first and only oral treatment in Europe specifically for patients with secondary progressive MS with active disease. What was the evidence? The drug approval… Read more »